{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001048477","name":"BIOMARIN PHARMACEUTICAL INC","summary":"BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company founded in 1997 and headquartered in San Rafael, California. The company develops and commercializes therapies for genetically defined conditions, with eight commercial products including VOXZOGO for achondroplasia, enzyme therapies VIMIZIM, NAGLAZYME, ALDURAZYME, and BRINEURA, as well as PALYNZIQ and KUVAN for PKU. BioMarin reported $3.2 billion in total revenues in 2025, driven significantly by VOXZOGO expansion.","people":[],"products":[{"name":"VOXZOGO (vosoritide)","type":"service","description":"Once daily CNP analog injection for treatment of achondroplasia in children with open growth plates."},{"name":"VIMIZIM (elosulfase alpha)","type":"service","description":"Enzyme therapy for Mucopolysaccharidosis type IVA (MPS IVA)."},{"name":"NAGLAZYME (galsulfase)","type":"service","description":"Enzyme therapy for Mucopolysaccharidosis type VI (MPS VI)."},{"name":"PALYNZIQ (pegvaliase-pqpz)","type":"service","description":"Therapy for Phenylketonuria (PKU)."},{"name":"ALDURAZYME (laronidase)","type":"service","description":"Enzyme therapy for Mucopolysaccharidosis type I (MPS I)."},{"name":"BRINEURA (cerliponase alfa)","type":"service","description":"Therapy for Neuronal ceroid lipofuscinosis type 2 (CLN2)."},{"name":"KUVAN (sapropterin dihydrochloride)","type":"service","description":"Therapy for Phenylketonuria (PKU)."},{"name":"ROCTAVIAN (valoctocogene roxaparvovec)","type":"service","description":"Gene therapy for severe Hemophilia A; voluntarily withdrawn from market in 2026."},{"name":"BMN 401 (formerly INZ-701)","type":"service","description":"Late-stage enzyme replacement therapy for ENPP1 deficiency, acquired via Inozyme acquisition."}],"partnerships":[{"partner_name":"Amicus Therapeutics, Inc.","partnership_type":"strategic","description":"Definitive agreement to acquire Amicus for $4.8 billion to add therapies for Fabry disease and late-onset Pompe disease.","start_date":null},{"partner_name":"Inozyme Pharma, Inc.","partnership_type":"strategic","description":"Acquisition completed July 2025 to add BMN 401, a late-stage enzyme replacement therapy for ENPP1 deficiency.","start_date":null}],"affiliations":[],"origin":{"leaf":"a7235121279624499f266974952d8770641cad78ce0b91dcfae85d6d8dad1034","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f0a7dd3f406bd607c245012dbc7e619ecfe194c60039886a75c47fe663a36dc8","parent":"c0722afa01ab3de1c62a2598760334f17e7523c881f49111c266140f7b41e641","source":"0001048477-26-000004","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}